Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics…
Increases Third Quarter Revenues 6% to $6.0 Billion Posts Third Quarter GAAP EPS of $0.83 and Non-GAAP EPS of $1.17…
– Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia…
– Roche to gain worldwide license to Dicerna’s novel RNAi therapy currently in Phase 1 – – Dicerna to receive…
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net…
DUBLIN–(BUSINESS WIRE)–The “Antibiotic Resistance Markets – Therapeutics By Pathogen and Therapy Type 2020 To 2024” report has been added to…
Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma…
CAMBRIDGE, England–(BUSINESS WIRE)–Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent)…
Signature of a framework agreement with Institut Pasteur in gene therapy Financial position strengthened with the issuance of a €20m…
FY2019 H1 revenue 1660.2 billion yen, up +88.5% versus prior year mainly due to acquisition of Shire and solid performance…